FitLife Brands Inc. (FTLF)
FTLF trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1374328/000143774926010680/0001437749-26-010680-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | FTLF on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001374328 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $81.5M |
| Net income | $6.3M |
| Operating income | $10.1M |
| Net margin | 7.8% |
| Operating margin | 12.4% |
| Revenue growth | +26.4% |
| Cash | $1.6M |
| Total assets | $106.3M |
| P/E (computed) | 10.1× |
| P/S (computed) | 0.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-13 |
| Cash and burn | $1.1M cash; operating cash flow $2.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 9,391,072 (2026-08-12); 9,391,072 a year earlier; 4,446,161 three years earlier. 3y figure adjusted for splits (2-for-1 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $75K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $26.5M | $1.9M | $3.6M | $1.1M | $6.1M | $35.7M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $25.3M | $1.7M | $2.5M | $1.2M | $6.1M | $25.3M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | -$39.6M | -$2.7M | $244K | $1.6M | $6.1M | $15.9M | 10-Q 2026-05-14 |
| Q3 2025 2025-09-30 | $23.5M | $921K | $3.7M | $3.5M | $46.5M | $70.6M | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $16.1M | $1.7M | $1.2M | $1.5M | $6.3M | $63.1M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $15.9M | $2.0M | $2.3M | $5.9M | $7.4M | $63.9M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $15.0M | $2.1M | $957K | $4.5M | $13.1M | $64.5M | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $16.0M | $2.1M | $2.0M | $4.7M | $9.7M | $62.8M | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2024-11-14 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-21 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-09-09 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-06-26 |
Source: SEC EDGAR submissions feed, 540 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.3% |
| 1 month | -6.5% |
| 3 months | -24.2% |
| Year to date | -47.9% |
| 1 year | -54.0% |
| From 52-week high | -54.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
| BTMD | Biote Corp. | $0.9603 | -9.83% | $34.5M |
| NAGE | Niagen Bioscience Inc. | $2.01 | -2.66% | $159.2M |
| MDWD | MediWound Ltd. | $13.55 | +5.04% | $195.0M |
| CGC | Canopy Growth Corporation Common Shares | $0.5460 | -2.71% | $231.2M |
| USNA | USANA Health Sciences Inc. | $13.54 | +2.27% | $250.3M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier